Pharmaceutical Preparations
243 US-listed companies SEC classification 2834 · all industries
How much this is one bet
34% of the closest matches for a typical Pharmaceutical Preparations company are other Pharmaceutical Preparations companies. That is moderate. The industry moves together to a degree, but individual companies still have plenty of their own story.
How the industry moves
Measured from one year of daily returns. Rate sensitivity is the median correlation between a company's daily return and the daily change in the 10-year Treasury yield: positive means the industry tends to rise on days yields rise. It is a correlation, not a forecast, and a low number over one year is a statement about this year.
On the public record
Insider filings Congressional trades Short interest Institutional holdings
The companieslargest 60 by daily turnover
| Ticker | Company | Traded per day | Beta | Days to cover |
|---|---|---|---|---|
| LLY | Eli Lilly and Company | $2.9B | 0.30 | 3.0 |
| JNJ | Johnson & Johnson | $1.8B | -0.07 | 3.3 |
| ABBV | AbbVie Inc. | $1.3B | -0.01 | 4.4 |
| MRK | Merck & Company, Inc. Common Stock (new) | $1.3B | 0.21 | 2.2 |
| PFE | Pfizer, Inc. | $954.8M | 0.27 | 4.3 |
| ABT | Abbott Laboratories | $929.9M | 0.08 | 2.7 |
| BMY | Bristol-Myers Squibb Company | $641.2M | 0.24 | 5.3 |
| VRTX | Vertex Pharmaceuticals Incorporated | $622.8M | 0.43 | 4.5 |
| REGN | Regeneron Pharmaceuticals, Inc. | $515.0M | 0.31 | 3.9 |
| AZN | AstraZeneca PLC Ordinary Shares | $482.9M | 0.16 | 1.0 |
| NVO | Novo Nordisk A/S | $451.9M | 0.97 | 2.7 |
| ZTS | Zoetis Inc. Class A | $379.2M | 0.61 | 4.1 |
| ALNY | Alnylam Pharmaceuticals, Inc. | $366.7M | 0.52 | 3.9 |
| INSM | Insmed Incorporated | $290.6M | 0.55 | 6.9 |
| UTHR | United Therapeutics Corporation | $270.7M | 0.40 | 4.8 |
| NVS | Novartis AG | $263.7M | 0.38 | 4.2 |
| ROIV | Roivant Sciences Ltd. | $214.6M | 1.15 | 3.8 |
| TEVA | Teva Pharmaceutical Industries Limited Ordinary Shares | $192.9M | 0.59 | 7.7 |
| BBIO | BridgeBio Pharma, Inc. | $185.2M | 0.96 | 11.2 |
| GSK | GSK plc American Preferred | $184.3M | 0.28 | 4.8 |
| JAZZ | Jazz Pharmaceuticals plc | $175.5M | 0.53 | 3.7 |
| RPRX | Royalty Pharma plc - Class A Ordinary Shares | $167.9M | 0.22 | 5.1 |
| AXSM | Axsome Therapeutics, Inc. | $151.2M | 0.63 | 5.8 |
| VTRS | Viatris Inc. | $150.4M | 0.66 | 5.3 |
| ASND | Ascendis Pharma A/S - Ordinary Share | $148.8M | 0.37 | 9.5 |
| IONS | Ionis Pharmaceuticals, Inc. | $148.3M | 0.35 | 9.2 |
| MDGL | Madrigal Pharmaceuticals, Inc. | $144.5M | 0.45 | 9.5 |
| CYTK | Cytokinetics, Incorporated | $132.1M | 0.98 | 9.7 |
| PRAX | Praxis Precision Medicines, Inc. | $125.3M | 1.59 | 10.2 |
| ONC | BeOne Medicines Ltd. | $124.4M | 0.71 | 4.2 |
| SNY | Sanofi | $123.8M | 0.27 | 4.0 |
| ABVX | Abivax SA | $120.1M | 1.17 | 8.0 |
| BMRN | BioMarin Pharmaceutical Inc. | $118.8M | 0.37 | 5.8 |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $118.1M | 1.39 | 8.8 |
| ELAN | Elanco Animal Health Incorporated | $115.1M | 1.32 | 6.4 |
| SYRE | Spyre Therapeutics, Inc. | $106.0M | 1.69 | 9.7 |
| LQDA | Liquidia Corporation | $105.8M | 0.89 | 10.2 |
| TGTX | TG Therapeutics, Inc. | $102.6M | 0.67 | 15.9 |
| CORT | Corcept Therapeutics Incorporated | $95.5M | 1.86 | 11.9 |
| TVTX | Travere Therapeutics, Inc. | $90.1M | 1.35 | 9.6 |
| GMAB | Genmab A/S | $86.5M | 0.93 | 2.4 |
| VKTX | Viking Therapeutics, Inc. | $84.0M | 1.34 | 12.4 |
| PTGX | Protagonist Therapeutics, Inc. | $82.6M | 0.92 | 15.3 |
| ALKS | Alkermes plc | $80.9M | 0.78 | 11.8 |
| DNTH | Dianthus Therapeutics, Inc. | $77.8M | 1.04 | 15.3 |
| ORKA | Oruka Therapeutics, Inc. | $77.3M | 1.50 | 9.3 |
| LGND | Ligand Pharmaceuticals Incorporated | $73.9M | 0.90 | 14.1 |
| SMMT | Summit Therapeutics Inc. | $73.4M | 1.93 | 6.6 |
| PTCT | PTC Therapeutics, Inc. | $73.3M | 0.81 | 12.1 |
| RYTM | Rhythm Pharmaceuticals, Inc. | $70.2M | 1.26 | 21.9 |
| SLS | SELLAS Life Sciences Group, Inc. | $69.4M | 2.26 | 6.9 |
| TNGX | Tango Therapeutics, Inc. | $68.5M | 1.53 | 19.7 |
| COGT | Cogent Biosciences, Inc. | $66.1M | 1.45 | 12.1 |
| ERAS | Erasca, Inc. | $65.5M | 1.56 | 9.4 |
| MIRM | Mirum Pharmaceuticals, Inc. | $63.2M | 1.10 | 13.2 |
| RARE | Ultragenyx Pharmaceutical Inc. | $58.0M | 1.42 | 8.0 |
| VERA | Vera Therapeutics, Inc. | $56.2M | 1.26 | 10.8 |
| ELVN | Enliven Therapeutics, Inc. | $54.4M | 1.09 | 11.1 |
| TAK | Takeda Pharmaceutical Company Limited American Preferred | $50.8M | 0.07 | 1.8 |
| EWTX | Edgewise Therapeutics, Inc. | $50.4M | 1.16 | 8.0 |
What “one bet” means, and how it is measured
For every security this site computes its closest matches across the whole market, by one-year daily-return correlation. Cohesion asks a simple question of that: of the ten closest matches for each company in this industry, what share are also in this industry?
A high number means the classification is doing real work — these companies genuinely move together, and the industry is closer to a single position than to a set of independent ones. Trucking, shipping, homebuilders and airlines sit at the top of that measure, which is what anyone who has held two of them would tell you.
A low number means the opposite: the SEC's code groups them, but the market does not. That is worth knowing before treating an industry label as a diversification plan.
Where these numbers come from
- The classification is the SEC's own Standard Industrial Classification, taken from each company's filings. It is coarse and occasionally odd — it was designed in 1937 and last seriously revised in 1987 — but it is the official one, it is public, and it is not somebody's proprietary sector scheme.
- Volatility, beta, rate and volatility sensitivity, and cohesion are computed here from daily returns. They are derived statistics; no price or return series is published anywhere on this site.
- Everything under “on the public record” is a count or a sum of filings — Form 4, the STOCK Act, Form 13F, FINRA short interest, USASpending awards, SEC financial statements. As filed.
What is deliberately absent
No index, no sector return, no performance figure. Aggregating company returns into an industry return would be republishing the licensed price history in a thin disguise, and it would also be wrong — there is no defensible weighting to choose. The statistics here are all invariant to that problem: a median, a correlation, a count, or a sum of filed figures.
All industries, ranked · each company's own page is under security pages.